InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.25
(
0.20%
)
US TECH 100
18,971.20
(
-0.03%
)
Dow Jones
40,659.76
(
0.24%
)
Brent Oil
79.07
(
0.29%
)
Bitcoin
58,560.85
(
0.17%
)
Post# of 252904
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Regulardoc

Send PM Follow Ignore
Followers 5
Posts 323
Boards Moderated 0
Alias Born 07/27/2010

Regulardoc

Re: jbog post# 118639

Thursday, 04/21/2011 10:46:30 AM

Thursday, April 21, 2011 10:46:30 AM

Post# of 252904
Agree. This is inappropriate collateral damage. It really affects TEVA's oral drug in development, rather than Copaxone unless proven to be far superior to Copaxone. We've known for the last two years that the orals are coming (and have come), so there should be no direct negative on MNTA. Additionally, any possible negative for Copaxone is 2-4 years down the road.

You buy when stocks go on sale. Actually purchased TEVA in pre-market for a daytrade.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up